NKGen Biotech (NKGN) News Today $0.14 -0.03 (-17.65%) As of 08/8/2025 12:03 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology SummitAugust 6 at 8:00 AM | globenewswire.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025July 29, 2025 | finance.yahoo.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025July 28, 2025 | globenewswire.comNKGen Biotech to Present at the Alzheimer's Association International Conference 2025July 22, 2025 | globenewswire.comNKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJuly 21, 2025 | finance.yahoo.comNKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to JapanJuly 17, 2025 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 17, 2025 | finanznachrichten.deNKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 16, 2025 | globenewswire.comNKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s ...July 12, 2025 | morningstar.comMNKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 11, 2025 | finanznachrichten.deNKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 10, 2025 | globenewswire.comNKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and FloridaJune 23, 2025 | globenewswire.comNkgen biotech sees $2.5 million stock purchase by major shareholderJune 4, 2025 | investing.comNKGen Biotech Enters Stock Purchase AgreementMay 20, 2025 | tipranks.comNKGen Biotech Chairman & CEO Paul Y. Song, M.D.May 8, 2025 | globenewswire.comNKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingMay 7, 2025 | finance.yahoo.comNKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & ExhibitionApril 14, 2025 | globenewswire.comNKGen Biotech presents data from Phase 1/2a trial of troculeucelApril 9, 2025 | markets.businessinsider.comNKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)April 7, 2025 | globenewswire.comNKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 ConferenceMarch 27, 2025 | nasdaq.comNKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)March 25, 2025 | markets.businessinsider.comNKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)March 25, 2025 | globenewswire.comNKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock splitMarch 4, 2025 | markets.businessinsider.comNKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be ImplementedMarch 4, 2025 | globenewswire.comNKGen Biotech announces administration of first dose of troculeucelMarch 3, 2025 | markets.businessinsider.comNKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use ProgramMarch 3, 2025 | globenewswire.comNKGen administers first troculeucel dose under compassionate use programFebruary 21, 2025 | markets.businessinsider.comNKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFebruary 21, 2025 | globenewswire.comNKGen Biotech appoints Anita Fletcher as PI for Phase 2a troculeucel trialFebruary 19, 2025 | markets.businessinsider.comNKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast SiteFebruary 19, 2025 | globenewswire.comNKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s DiseaseFebruary 13, 2025 | markets.businessinsider.comNKGen Biotech announces publication of Phase 1 troculeucel trial resultsFebruary 13, 2025 | markets.businessinsider.comNKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's DiseaseFebruary 13, 2025 | globenewswire.comNKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s DiseaseFebruary 12, 2025 | finance.yahoo.comFDA Fast Track Designation Sends Biotech Soaring Mid-WeekFebruary 12, 2025 | msn.comFDA fast tracks NKGen's Alzheimer's therapy troculeucelFebruary 12, 2025 | msn.comNKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's DiseaseFebruary 12, 2025 | globenewswire.comNKGen Biotech, Inc. (NKGN)January 25, 2025 | ca.finance.yahoo.comNKGen Biotech Awards Stock Options to ExecutivesDecember 12, 2024 | markets.businessinsider.comNKGen Biotech Secures Key Role in NKMax DealDecember 3, 2024 | markets.businessinsider.comNKGen Biotech Selected as Stalking Horse Bidder for NKMaxDecember 2, 2024 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNovember 29, 2024 | finanznachrichten.deNKGen Biotech gets Nasdaq notice related to delayed quarterly reportNovember 28, 2024 | markets.businessinsider.comNKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNovember 26, 2024 | globenewswire.comNKGen Flat on Presentation of Alzheimer's TreatmentOctober 30, 2024 | baystreet.caNKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 29, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)October 15, 2024 | globenewswire.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 8, 2024 | finance.yahoo.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 8, 2024 | globenewswire.comNKGen Biotech (NASDAQ:NKGN) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.com Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address NKGN Media Mentions By Week NKGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKGN News Sentiment▼-0.500.45▲Average Medical News Sentiment NKGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKGN Articles This Week▼21▲NKGN Articles Average Week Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dyadic International News Iterum Therapeutics News Estrella Immunopharma News Kezar Life Sciences News OnKure Therapeutics News Cingulate News FibroGen News Tempest Therapeutics News SCYNEXIS News MIRA Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NKGN) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKGN Stock Alerts